Cas9 / HP1-gamma fusion protein for improving gene editing efficiency and method and system thereof
By constructing the Cas9/HP1-γ fusion protein, the problem of CRISPR-Cas9 is low in knocking in large fragments is solved, which significantly improves the efficiency of homologous recombination and improves the effect of cell therapy.
Patent Information
- Application Number
- CN202410398409.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-03
- Publication Date
- 2024-11-08
AI Technical Summary
In traditional cell therapy, the CRISPR-Cas9 gene editing tool is less efficient when knocking in large fragments, which increases the difficulty and cost of cell therapy. The existing Cas9-fusion proteins have limited improvement in the repair efficiency of homologous recombination.
By constructing the Cas9/HP1-γ fusion protein, the small molecule protein of HP1-γ is fused with the Cas9 protein, improving the efficiency of directed homologous recombination and reducing the risk of immune rejection to cells.
It significantly improved the efficiency of gene knock-in of CRISPR-Cas9, enhanced the efficiency of targeted homologous recombination, and reduced the cost and complexity of cell therapy.
Smart Images

Figure CN118909133A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of genetic engineering technology, and specifically relates to a Cas9 / HP1-γ fusion protein for improving gene editing efficiency and a method and system thereof. Background Art
[0002] Cell therapy is a method of treating patients by culturing edited cells in vitro and then infusing them back into the patient's body. It has made considerable progress in the treatment of cancer and genetic diseases. However, the traditional method of editing cells in vitro mainly uses lentiviral infection, which has disadvantages such as random DNA site integration (which may cause cell canceration) and strong immunogenicity (which may cause immune rejection of the infusing patient).
[0003] As a newly discovered gene editing tool, CRISPR-Cas9 can specifically edit specific DNA sites. At the same time, it has higher editing efficiency than TALEN and ZFN, and the operation method is simpler. Therefore, it has good application prospects in cell therapy. Although CRISPR has a high efficiency in gene knockout, it has a low efficiency when knocking in large fragments, which increases the difficulty and cost of screening positive cells and greatly reduces its application in the field of cell therapy. Large-end knock-in mainly depends on the homologous recombination repair pathway, so it is necessary to develop a gene editing tool that can improve the efficiency of homologous recombination. Existing literature reports suggest that the cas9-fused CTIP protein fragment (including various truncations) has a better effect on improving homologous recombination, and the fusion fragment size can only reach about 2 times the efficiency when it is 294 residues. This study suggests that compared with Cas9-fused large fragment protein, Cas9-fused small molecule protein may improve the efficiency of homologous recombination.
[0004] Heterochromatin-associated protein 1-γ (HP1-gamma, HP1-γ) is a small molecule protein with only 190 residues. It is a member of the heterochromatin-associated protein 1 (HP1) family; the family also includes HP1-α and HP1-β. They are involved in a series of cellular physiological processes such as cell senescence, DNA repair, cell cycle, cell differentiation and tumor formation. Through research, it has been found that HP1-γ may be expressed at elevated levels in a variety of tumor tissues, such as lung cancer, breast cancer, ovarian cancer, colorectal cancer, esophageal cancer, prostate cancer, etc. Although HP1-γ has been reported to participate in the homologous recombination repair (HR) pathway in cells, at the same time, literature data show that overexpression of HP1-γ protein alone will reduce the overall homologous recombination repair efficiency of cells. The above studies show that HP1-γ plays an important role in the proliferation and survival of cancer cells and their ability to form tumors in vivo.
[0005] Based on the above studies, a Cas9-fused HP1-γ protein is expected to be used to detect its efficiency in directed homologous recombination. Summary of the invention
[0006] The purpose of the present invention is to overcome the problems existing in the prior art and provide a Cas9 / HP1-γ fusion protein expression vector and a construction method and application thereof that improve the efficiency of gene editing. The present invention improves the efficiency of gene knock-in by the CRISPR-Cas9 method by constructing a Cas9 / HP1-γ fusion protein expression vector, thereby providing help for the application of CRISPR-Cas9 in the field of in vitro cell editing.
[0007] The purpose of the present invention and the solution to the technical problem are achieved by adopting the following technical solutions.
[0008] The first aspect of the present invention provides a Cas9 / HP1-γ fusion protein, wherein the fusion protein is a Cas9 protein fused to an HP1-γ protein at the N-terminus or C-terminus of the Cas9 protein, wherein the Cas9 protein and the HP1-γ protein are connected via a G4S linker.
[0009] In some preferred embodiments of the present invention, the Cas9 protein comprises the amino acid sequence shown in SEQ ID NO.1.
[0010] In some preferred embodiments of the present invention, the HP1-γ protein comprises:
[0011] (1) the amino acid sequence of SEQ ID NO.2;
[0012] (2) an amino acid sequence in which one or more amino acid residues are added, deleted, substituted or inserted into the amino acid sequence of SEQ ID NO. 2; or
[0013] (3) An amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO.2.
[0014] In some preferred embodiments of the present invention, the fusion protein comprises the amino acid sequence shown in SEQ ID NO.3.
[0015] The second aspect of the present invention provides a coding gene, which encodes the aforementioned Cas9 / HP1-γ fusion protein.
[0016] The third aspect of the present invention provides a Cas9 / HP1-γ fusion protein expression vector, which contains the aforementioned encoding gene.
[0017] The third aspect of the present invention provides a host cell, which contains the aforementioned Cas9 / HP1-γ fusion protein expression vector, or contains the aforementioned coding gene, or contains the aforementioned Cas9 / HP1-γ fusion protein. Preferably, the host cell is an animal cell, a plant cell or a microbial cell.
[0018] The fourth aspect of the present invention provides a method for producing a Cas9 / HP1-γ fusion protein, comprising the following steps:
[0019] (1) culturing the aforementioned host cell under conditions suitable for culturing the host cell; and
[0020] (2) Harvesting the fusion protein of the present invention.
[0021] The fifth aspect of the present invention provides a gene editing system, which includes the aforementioned Cas9 / HP1-γ fusion protein, a coding gene, or a Cas9 / HP1-γ fusion protein expression vector, and gRNA.
[0022] The sixth aspect of the present invention provides a gene editing method, characterized in that it includes the step of introducing the aforementioned Cas9 / HP1-γ fusion protein, encoding gene, or Cas9 / HP1-γ fusion protein expression vector into a target cell, wherein the target cell is an immune cell or a pluripotent stem cell, and preferably, the target cell is a 293T cell.
[0023] The seventh aspect of the present invention provides a method for genetically modifying cells, which comprises the step of introducing the aforementioned Cas9 / HP1-γ fusion protein, encoding gene, or Cas9 / HP1-γ fusion protein expression vector into a target cell, wherein the target cell is an immune cell or a pluripotent stem cell, and preferably, the target cell is a 293T cell.
[0024] The seventh aspect of the present invention provides a use of a cell in preparing a drug, wherein the cell is a cell that has been gene-edited or modified according to the aforementioned method, and the drug is used to treat a disease in a subject in need of the cell, the disease including cancer or autoimmune disease.
[0025] In some preferred embodiments of the present invention, the cancer includes but is not limited to colorectal cancer, leukemia, lymphoma (Hodgkin and non-Hodgkin), myeloma and myeloproliferative diseases, sarcoma, melanoma, adenoma, squamous cell carcinoma of the oral cavity, pharynx, laryngeal cancer and lung cancer, liver cancer, prostate cancer, cervical cancer, bladder cancer, uterine cancer and endometrial cancer, as well as renal cell carcinoma, bone cancer, pancreatic cancer, skin cancer, cutaneous or intraocular melanoma, thyroid cancer, parathyroid cancer, head and neck cancer, breast cancer, gastrointestinal cancer and nervous system cancer, papilloma, etc.
[0026] In some preferred embodiments of the present invention, the autoimmune disease includes but is not limited to chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis, acute idiopathic polyneuritis, systemic lupus erythematosus, rheumatoid arthritis, polyarteritis nodosa, scleroderma, dermatomyositis, etc.
[0027] The eighth aspect of the present invention provides an application of the aforementioned Cas9 / HP1-γ fusion protein, encoding gene, or Cas9 / HP1-γ fusion protein expression vector or gene editing system in improving gene editing efficiency.
[0028] By means of the above technical scheme, the present invention has at least the following advantages: the protein HP1-γ selected by the present invention for fusion with CRISPR-Cas9 is relatively small, with only 190 residues, so the length of the protein will not be significantly increased after fusion with the CRISPR-Cas9 protein, and thus has almost no negative impact on delivery.
[0029] It has been verified through experiments that the Cas9-HP1-γ fusion protein of the present invention can achieve specific directional overexpression, which will not only not lead to a decrease in the efficiency of homologous recombination repair (HR), but will significantly improve the efficiency of directional homologous recombination.
[0030] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the preferred embodiments of the present invention are described in detail as follows. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 This is a schematic diagram of the structure of the Cas9-HP1-γ fusion protein of the present invention;
[0032] Figure 2 is the result of flow cytometry, wherein 26 is the Cas9-HP1-γ fusion protein of the present invention;
[0033] Figure 3 For comparison of knock-in efficiency, WTcas9 is the original cas9 protein, and Cas9-HP1-γ is the fusion protein of the present invention;
[0034] Figure 4 To detect cell viability after fusion protein transfection. DETAILED DESCRIPTION
[0035] In order to make the technical means, creative features, objectives and effects of the present invention easy to understand, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0036] As described in the present invention, the Cas9 protein comprises the amino acid sequence shown in SEQ ID NO.1 and the nucleotide sequence shown in SEQ ID NO.4.
[0037] SEQ ID NO.1
[0038]
[0039] SEQ ID NO.4
[0040]
[0041] According to the present invention, the HP1-γ protein comprises:
[0042] (1) the amino acid sequence of SEQ ID NO.2;
[0043] (2) an amino acid sequence in which one or more amino acid residues are added, deleted, substituted or inserted into the amino acid sequence of SEQ ID NO. 2; or
[0044] (3) An amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO.2.
[0045] SEQ ID NO.2
[0046] GKKTKRTADSSSEDEEEYVVEKVLDRRVVKQVEYLLKWKGFSEEHNTWEPEKNLDCPELISEFMKKYKKMKEGENNKPREKSESNKRKSNFSNSADDIKSKKKREQSNDIARGFERGLEPEKIIGATDSCGDLMFLMKWKDTDEADLVLAKEANVKCPQIVIAFYEERLTWHAYPEDAENKEKETAKSGS.
[0047] Example 1: Construction of Cas9-HP1-γ fusion protein plasmid
[0048] The construction process of pGE26 expression vector is as follows:
[0049] 1) The nucleotide sequence of HP1-γ was taken from the NCBI database, and its amino acid sequence is shown in SEQ ID NO.2. To prevent the fusion proteins from affecting each other's folding, a G4S linker sequence as shown in SEQ ID NO.5 was inserted between the two fusion proteins. The G4S linker-HP1-γ sequence was then synthesized by Sangon Biotech (Shanghai) Co., Ltd. to obtain a G4S linker-HP1-γ as shown in SEQ ID NO.6.
[0050] SEQ ID NO.5
[0051] GGGGSGGGGSGGGGSGGGGS.
[0052] SEQ ID NO.6
[0053] GaattcggtggtggcggctctggtggcggtggcagcggcggtggtggttccggaggcggcggatccGGGAAAAAGACCAAGCGCACAGCCGATTCCTCATCCAGCGAGGATGAGGAGGAGTACGTGGTCGAAAAGGTCCTGGATCGGAGGGTGGTCAAGG GCCAGGTGGAGTACCTCCTGAAGTGGAAGGGGTTTAGCGAGGAGCACAACACCTGGGAGCCCGAGAAGAACTTGGACTGCCCCGAGCTGATCAGCGAGTTCATGAAGAAGTACAAGAAGATGAAGGAGGGGGAGAACAACAAGCCCAGGGAGAAGAGCGAG AGCAACAAGAGGAAGAGCAACTTCAGCAACAGCGCCGATGATATCAAGAGCAAGAAGAAGCGGGAGCAGAGCAACGATATCGCCAGGGGCTTCGAGAGGGGCCTGGAGCCCGAGAAGATCATCGGGGCCACCGATAGCTGCGGCGACCTGATGTTCCTGA TGAAGTGGAAGGACACAGACGAGGCCGACCTGGTGCTGGCCAAGGAGGCCAACGTGAAGTGCCCCCAGATCGTGATCGCCTTCTACGAGGAGCGGCTGACATGGCACGCCTACCCCGAGGACGCCGAGAACAAGGAGAAGGAGACCGCCAAGAGCggatcc
[0054] 2) Using pX458 (purchased from addgene) as the expression backbone, the px458 plasmid was cut with EcoRI (purchased from neb), and the cleavage product was recovered and connected with the G4Slinker-HP1-γ sequence synthesized by the above-mentioned biotechnology through homologous recombinase (purchased from Novozymes) to obtain the Cas9-G4Slinker-HP1-γ fusion sequence with an amino acid sequence as shown in SEQ ID NO.3.
[0055] SEQ ID NO.3
[0056]
[0057] 3) The constructed plasmid was submitted to Sangon Biotech (Shanghai) Co., Ltd. for sequencing, and the plasmid with correct sequencing was named pGE26.
[0058] Example 2: Construction of targeting plasmid
[0059] 1) The 3'UTR of ACTB was selected as the target site, and the target sequence was designed and then submitted to Shanghai Bioengineering Co., Ltd. for synthesis;
[0060] The targeting sequence is shown in SEQ ID NO.7: (ACTB 3'UTR) GGTAACAACGCATCTCATATT.
[0061] 2) Prepare a 10uM aqueous solution of the target sequence F / R, take 10uL of each and mix well, then heat the mixture at 95°C for 5-10min, and then let it stand at room temperature to cool and anneal;
[0062] 3) Cut the plasmid pGE26 with bbsi (purchased from neb) and recover the cut product;
[0063] 4) Use T4 ligase (purchased from NEB) to connect the annealed product and the cleavage recovery product;
[0064] 5) The obtained targeting plasmid was sent to Shanghai Sangon Biotech Co., Ltd. for sequencing, and the correctly sequenced plasmid was named pGE26-ACTB.
[0065] Example 3: Construction of GFP gRNA donor plasmid
[0066] The EFP gRNA target site was gttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgc (SEQ ID NO. 8), and a GFP gRNA expression vector was constructed. The vector was synthesized and constructed by Nanjing GenScript Biotechnology Co., Ltd. and named 3-07.
[0067] Example 4: Cell co-transfection
[0068] 1) 293T cells were seeded into a 12-well plate at 1E5 / well and 1 mL / well complete medium (DMEM + 10% FBS) was added and cultured for 24 h;
[0069] 2) Add plasmids pGE26 and 3-07 at a mass ratio of 1:1 (1ug in total) to 50uL serum-free DMEM and incubate at room temperature for 5 minutes. Then, add 2uL 1ug / uL PEI to the plasmid mixture and mix well. Let stand at room temperature for 10 minutes.
[0070] 3) Operate the wtspCas9 plasmid and the 3-07 plasmid according to the steps in 2);
[0071] 4) Replace the cells in 1 with 1 mL of fresh complete medium, then evenly inoculate the mixture in 2 and 3 into different wells, and replace with fresh medium after culturing for 24 hours.
[0072] Example 5: Flow cytometry detection
[0073] Seven days after the above cells were co-transfected, the old culture medium was removed from the transfected cells, and an appropriate amount of PBS was added for washing. After trypsin digestion, the cells were collected by centrifugation, the supernatant was removed, and the cells were washed twice with PBS and resuspended. The GFP expression in the cells was detected by flow cytometry to determine the knock-in efficiency. Figure 2 and 3 shown.
[0074] Figure 2 In the embodiment, 26 is the Cas9-HP1-γ fusion protein of the present invention. Figure 2 and 3 As shown, the knock-in efficiency of the cas9-HP1g fusion protein of the present invention is significantly increased.
[0075] Example 6: Cell viability detection
[0076] 1. Experimental methods:
[0077] (1) 293T cells were evenly plated on a 12-well plate to a cell density of 50%;
[0078] (2) Co-transfection of Cas9(-hp1g) plasmid (containing green fluorescent protein tag) into 293T cells;
[0079] (3) After 48 hours, CCK8 reagent was used to detect cell viability.
[0080] 2. Experimental results:
[0081] CCK-8 was used to detect the viability of 293T cells. The results are shown in Figure 4 . Figure 4 The control is the original Cas9 protein, and PGE-26 is the fusion protein with the most significant knock-in efficiency. As can be seen from the data in the figure, there is no significant difference in cell viability between the experimental group and the control group.
[0082] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with this profession can make some changes or modifications to equivalent embodiments of equivalent changes by using the methods and technical contents disclosed above without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent change and modification made to the above embodiments according to the technical essence of the present invention without departing from the content of the technical solution of the present invention still fall within the scope of the technical solution of the present invention.
Claims
1. Cas9 / HP1-γ fusion protein, characterized in that The fusion protein is a fusion of HP1-γ protein to the N-terminus or C-terminus of the Cas9 protein, wherein the Cas9 protein and the HP1-γ protein are connected via a G4S linker, and the Cas9 protein comprises the amino acid sequence shown in SEQ ID NO.
1.
2. The fusion protein according to claim 1, characterized in that The HP1-γ protein comprises: (1) the amino acid sequence of SEQ ID NO.2; (2) an amino acid sequence in which one or more amino acid residues are added, deleted, substituted or inserted into the amino acid sequence of SEQ ID NO. 2; or (3) An amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO.
2.
3. The Cas9 / HP1-γ fusion protein according to any one of claims 1 to 2, characterized in that The fusion protein comprises the amino acid sequence shown in SEQ ID NO.
3.
4. A coding gene encoding the Cas9 / HP1-γ fusion protein according to any one of claims 1 to 3.
5. A Cas9 / HP1-γ fusion protein expression vector, which comprises the coding gene according to claim 4.
6. A host cell, comprising the Cas9 / HP1-γ fusion protein expression vector of claim 5, the encoding gene of claim 4, or the Cas9 / HP1-γ fusion protein of any one of claim 13, preferably, the host cell is an animal cell, a plant cell or a microbial cell.
7. A gene editing system, characterized in that: The gene editing system comprises the Cas9 / HP1-γ fusion protein of any one of claims 1 to 3, the encoding gene of claim 4, or the Cas9 / HP1-γ fusion protein expression vector of claim 5, and gRNA.
8. A gene editing method, characterized in that: The method comprises the step of introducing the Cas9 / HP1-γ fusion protein of any one of claims 1 to 3, the encoding gene of claim 4, or the Cas9 / HP1-γ fusion protein expression vector of claim 5 into a target cell, wherein the target cell is an immune cell or a pluripotent stem cell, and preferably, the target cell is a 293T cell.
9. A method for genetically modifying cells, characterized in that: The method comprises the step of introducing the Cas9 / HP1-γ fusion protein of any one of claims 1 to 3, the encoding gene of claim 4, or the Cas9 / HP1-γ fusion protein expression vector of claim 5 into a target cell, wherein the target cell is an immune cell or a pluripotent stem cell, and preferably, the target cell is a 293T cell.
10. Use of the Cas9 / HP1-γ fusion protein according to any one of claims 1 to 3, the encoding gene according to claim 4, the Cas9 / HP1-γ fusion protein expression vector according to claim 5, or the gene editing system according to claim 7 in improving gene editing efficiency.
